{"id":"NCT01353703","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","officialTitle":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa™ Vaccine in Healthy Infants in India","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04-16","primaryCompletion":"2013-02-25","completion":"2013-02-25","firstPosted":"2011-05-16","resultsPosted":"2019-01-25","lastUpdate":"2020-01-02"},"enrollment":224,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis","Tetanus","Acellular Pertussis","Haemophilus Influenzae Type b","Diphtheria","Hepatitis B","Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Infanrix hexa™","otherNames":["DTPa-HBV-IPV/Hib"]}],"arms":[{"label":"INFANRIX HEXA 6-10-14 GROUP","type":"EXPERIMENTAL"},{"label":"INFANRIX HEXA 2-4-6 GROUP","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-HBV-IPV/Hib) when administered as a primary vaccination course to Indian infants according to a 6-10-14 weeks or a 2-4-6 months schedule.","primaryOutcome":{"measure":"Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens","timeFrame":"One month post Dose 3 (Month 3 or Month 5)","effectByArm":[{"arm":"Infanrix Hexa 6-10-14 Group","deltaMin":105,"sd":null},{"arm":"Infanrix Hexa 2-4-6 Group","deltaMin":106,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":4,"countries":["India"]},"refs":{"pmids":["27629913"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":112},"commonTop":["Pain","Pyrexia","Upper respiratory tract infection","Irritability","Swelling"]}}